Five poliovirus recombinants containing sequences corresponding to foot-and-mouth disease virus (FMDV) antigenic sites were constructed. Viable virus was recovered from four of these plasmids, in which the VP1 WB-kC loop (antigenic site 1) of poliovirus type 1 Sabin had been replaced with sequences derived from the VP1 OiG-IH loop (antigenic site 1) of FMDV 01 Kaufbeuren (01K), chimera 01.1 (residues 141 to 154), chimera 01.2 (residues 147 to 156), and chimera 01.3 (residues 140 to 160) or from the IIB-IC loop of VP1 (antigenic site 3) in chimera 03.1 (residues 40 to 49). One chimera (01.3) was neutralized by FMDV-specific polyclonal serum and monoclonal antibodies directed against antigenic site 1 of FMDV. Chimeras 01.3 and 03.1 induced site-specific FMDV-neutralizing antibodies in guinea pigs. Chimera 01.3 was capable of inducing a protective response against FMDV challenge in some guinea pigs.
antigenic site. The ability of such a sequence to induce an immune response capable of conferring protection against challenge from its parental pathogen has not been demonstrated.
Four functionally distinct antigenic sites have been defined in the 01 Kaufbeuren (01K) strain of FMDV (12, 15) . Site 1 corresponds to the residue 140 to 160 region (the large 1G-PH loop) and the carboxy terminus of VP1 (up to residue 213); key residues have been shown to be 144, 148, and 154 and 208, respectively. Most MAbs which recognize this site also recognize isolated VP1 and the 140-to 160-residue peptide derived from it. In the crystallographic structure of type 0 FMDV, this region has not been resolved (1) ; this probably reflects variability in the conformation of this loop.
The 140-to 160-residue peptide has been shown to induce a protective response in guinea pigs (4) , and thus a chimera containing this sequence would provide a useful tool for determination of the potential of chimeric picornaviruses as alternative antigen presentation systems. The other sites are much more dependent on the structural integrity of the virus particle. Site 2 has been mapped by escape mutations to the ,B-,C loop of VP2, and site 4 has been mapped to the knob in VP3 (residues 56 and 58). Site 3 is found on the PB-,BC loop of VP1 (residues 43 to 45) and behaves totally independently from site 1 (12, 15) . In other studies, substitutions have been identified at residues 43 and 48 of VP1 in MAbresistant variants of the closely related virus 01 BFS 1860 (2) . However, this MAb was also reported to react with peptides from the residue 140 to 160 region of VP1 in an antigen inhibition enzyme-linked immunosorbent assay (ELISA) and it was concluded that these mutations were "acting at a distance" by inducing a conformational change viruses. We show that residues corresponding to FMDV sites 1 and 3 can be appropriately presented on the surface of poliovirus and can independently induce site-specific anti-FMDV neutralizing antibodies, thus supporting the view that these regions of FMDV are separate antigenic sites.
MATERIALS AND METHODS Construction of poliovirus/FMDV antigen chimeras. Poliovirus/FMDV chimeras were constructed by using the pCAS-1 Sabin 1-based expression vector (6) , which contains unique Sall and DraI restriction sites. Synthetic oligonucleotides were synthesized on an Applied Biosystems 381A machine. Complementary oligonucleotides were annealed and ligated with Sall-Dral-digested pCAS-1 and used to transform competent Escherichia coli MC1061 cells as previously described (6) . For chimera 01.3, four oligonucleotides were used to specify the FMDV sequence and were annealed and ligated into the vector in the same manner. In each case, introduction of the oligonucleotides was confirmed by DNA sequence analysis.
Recovery of viable poliovirus/FMDV chimeras. The recombinant pCAS-1/FMDV plasmids were linearized with NaeI, which cuts within vector sequences of the construct, and used as the template in a T7 transcription reaction (40) . The RNA transcription reaction product was transfected into subconfluent HEp-2C monolayers by using DEAE-dextran. A cytopathic effect was observed 2 to 5 days following transfection. Purified RNA from recovered chimeric virus was sequenced through antigenic site 1 by the dideoxy-chain termination method (35, 43) . The growth characteristics of the chimeras were determined as described previously (11) .
MAbs and polyclonal serum. The FMDV-specific MAbs (B2, C8, D7, D9, 04, 010, 13DB, 13DD, and LMK1) and guinea pig polyclonal serum used have been described previously (15) . Poliovirus-specific MAbs (21, 22) and rabbit and human poliovirus type 1-specific polyclonal serum were a gift from K. Katrak (National Institute for Biological Standards and Control, South Mimms, England). Guinea pig polyclonal serum raised against a synthetic peptide corresponding to FMDV VP1 residues 140 to 160 was a gift from T. Doel (Institute for Animal Health, Pirbright, England.
Virus neutralization assays. Plaque reduction neutralization assays were performed as described previously (42) .
Neutralization titers were expressed as reciprocal log1o antibody dilutions that neutralized 103 PFU of virus by 50%.
ELISA. FMDV sandwich ELISAs were performed essentially as previously described (17) . Serum from guinea pigs immunized with poliovirus chimeras was pretreated with whole bovine serum-agarose (Sigma Chemicals Ltd., Poole, England) to remove nonspecific antibodies. ELISA antibody titers were expressed as reciprocal log1o antibody dilutions which gave an optical density values of 0.4 above the background.
Guinea pig immunization and FMDV challenge. Guinea pigs (Dunkin Hartley) were inoculated subcutaneously with 2 to 5 ,ug of sucrose gradient-purified virus in 0.1 ml of Freund complete adjuvant, and 28 days later the guinea pigs were inoculated with a second dose of 2 to 5 jig of purified virus in Freund incomplete adjuvant. The guinea pigs were challenged with 1,000 guinea pig-infectious doses of guinea pig-adapted 01 K FMDV 42 days post initial inoculation.
Guinea pigs were examined daily for 7 days for the appearance of lesions following FMDV challenge. Serial bleeds were taken on days 0 (preinoculation), 14, 28 (preboost), 42 (prechallenge), and 49 (postchallenge). The second immuni- (32) .
Selection of neutralization-resistant variants. Neutralization-resistant variants of chimera 01.3 were selected by using the procedure for the selection of poliovirus mutants described previously (23) . Presumptive mutants were plaque purified once and screened by using the selecting antibody.
RESULTS
Construction of poliovirus/FMDV antigen chimeras. The oligonucleotide sequences inserted into the pCAS vector are shown in Fig. 1 (3, 39, 42) . The sequence of type A1o FMDV was chosen, as this had been shown to react with MAb 18 in a pepscan assay (19) . The 3 (12) . Antigenic site 3 of FMDV is analogous to antigenic site 1 of poliovirus; in the three-dimensional structure of these viruses, these antigenic sites (on the 3B-,C loop of VP1) are located around the fivefold axis of the virion. The size of the PB-1C loop is increased by one amino acid in this chimera.
Recovery of viable virus. A cytopathic effect was observed 2 to 5 days following transfection of HEp-2c monolayers with RNA transcripts of constructs 01.1, 01.2, 01.3, and 03.1. The nucleotide sequence of the recovered virus around the region encoding poliovirus antigenic site 1 was determined by sequencing of purified viral RNA and found to be correct for all four recovered chimeric viruses (data not shown). Recombinant AMC.1, containing residues 200 to 213 of FMDV VP1, failed to produce virus following repeated transfection experiments, although the DNA sequence of the engineered site was correct.
Growth characteristics of the recovered viruses. The growth efficiencies of recovered viruses 01.3 and 03.1 were compared with that of unmodified Sabin type 1 poliovirus in a one-step growth curve experiment (Fig. 2) . Replication of both chimeras was slightly impaired compared with type 1 Sabin virus; chimeras 01.3 and 03.1 produced maximum titers of 1081 and 1086 PFU/ml, respectively, compared with a titer of 109 PFU/ml for type 1 Sabin virus. Chimeras 01.1 and 01.2 displayed growth characteristics similar to those of chimera 03.1 (data not shown). The plaque morphologies of the different chimeras were indistinguishable from those of Sabin type 1 virus.
Antigenic properties. The antigenic characteristics of the chimeras were assessed in neutralization and immune diffusion assays. Assays using poliovirus type 1-specific MAbs (21, 22) demonstrated loss of reactivity with antigenic site 1-specific MAbs 952 and 955 but retained reactivity with MAbs directed against poliovirus antigenic sites 2 and 3 (data not shown). Chimeras containing sequences corresponding to FMDV antigenic site 1 were tested against anti-FMDV MAbs B2, D7, D9, 13DB, and 13DD (which are specific for FMDV site 1) (12), guinea pig polyclonal hyperimmune anti-01 K FMDV serum, and guinea pig polyclonal antiserum to the synthetic peptide (01 K VP1 residues 140 to 160). Chimera 01.3 (containing the entire residue 140 to 160 region) was neutralized efficiently by MAbs B2, D7, and None of the chimeras reacted with MAbs specific for FMDV antigenic site 2 or 4 in immune diffusion assays (data not shown).
Selection of neutralization-resistant variants of chimera 01.3. As shown above, chimera 01.3 was neutralized by both anti-FMDV MAbs and polyclonal serum. To determine whether the FMDV sequence in this chimera was recognized in the same manner in the chimera as in FMDV itself, neutralization-resistant variants of chimera 01.3 were selected by using FMDV-specific MAbs B2, D7, and 13DB and polyclonal serum. Of six presumptive mutants analyzed, two were resistant to the selecting antibody. Mutant 01.3/M6 was selected with MAb 13DB, and mutant 01.3/M9 was selected with guinea pig polyclonal anti-FMDV serum. The phenotypes of these two independent variants were identical when examined by a plaque reduction neutralization assay using a panel of anti-FMDV antibodies (Fig. 3, top) . Sequence analysis of purified virion RNA through this region of VP1 identified a single amino acid substitution of proline to leucine at residue 102 (equivalent to residue 148 in the FMDV sequence) in both chimera variants (Fig. 3, bottom) . This is known to be a key residue in the region of FMDV recognized by these antibodies (42) .
Immunogenicity of poliovirus/FMDV chimeras. The polio- virus/FMDV chimeras were tested for the ability to stimulate production of FMDV-specific antibodies and confer protection against FMDV challenge in two immunization experiments. The first experiment involved immunization of five groups of four guinea pigs with 2 to 5 ,ug of purified immunogen (see Materials and Methods). Each set of animals was immunized with two doses of chimera or Sabin virus (control group) on days 0 and 28. The animals were challenged with 01 K FMDV 42 days post initial inoculation and observed for the appearance of FMDV-specific lesions. Sera obtained from serial bleeds were tested for the presence of FMDV-specific antibodies in ELISA and virus neutralization assays. Sera from guinea pigs immunized with chimera 01.3 possessed prechallenge FMDV neutralization titers of 1.1 to 2.8 (log1o reciprocal antibody dilution) ( Table   2 ). One (4R) of four guinea pigs immunized with this chimera was protected against FMDV challenge, and antiserum from this animal possessed the highest FMDV-neutralizing and ELISA antibody titer before challenge ( Table 2 ). The development of the neutralizing anti-FMDV antibody response in this guinea pig is shown in Fig. 4A . The anti-FMDV response was increased postchallenge, indicating that the animal had received FMDV although no disease was detected.
The response to chimera 03.1 was more variable: two guinea pigs showed almost no FMDV-specific response in both neutralization assays and ELISA, while animal 3R possessed low levels of FMDV-neutralizing antibody. However, guinea pig 3Y was partially protected against FMDV challenge; only 1 lesion appeared 5 days postchallenge (compared with 6 to 13 lesions in nonprotected animals). This animal also possessed the second highest prechallenge anti-FMDV neutralizing antibody titer (log1o reciprocal antibody dilution, 1.6) ( Table 2) . Guinea pigs immunized with chimera 01.1 or 01.2 were not protected against FMDV challenge; prechallenge sera from these animals reacted weakly, or not at all, with FMDV in ELISA or virus neutralization assays (Table 2) . Control guinea pigs which received two doses of Sabin virus were also not protected against FMDV challenge, and sera from these animals did not contain FMDV-specific antibodies. Prechallenge sera from the guinea pigs were also tested for the presence of poliovirus-neutralizing antibodies, and all of the animals possessed significant levels of poliovirus-neutralizing antibodies; however, the neutralizing titers of sera from guinea pigs immunized with either chimera 01.1 or 01.2 were lower than those of sera from the other animals ( Table 2 antibody titer against FMDV was observed with this assay (Fig. 4D) .
DISCUSSION
Five poliovirus/FMDV recombinant plasmids were constructed, and viable chimeric virus was recovered from four of these. The reasons for the nonviability of construct A1C.1 are unclear; however, it has been suggested that the presence of basic residues at the amino end of the 3B-3C loop compromises virus viability (4a). Although chimera 01.3 shows reduced virus yield compared with wild-type Sabin type 1 poliovirus, the replacement of 9 amino acids in the wild-type sequence with 21 amino acid residues in the chimera demonstrates the remarkable flexibility of the PB-PC of poliovirus VP1 to accommodate extensive foreign amino acid sequences.
The three chimeras containing sequences from the pG-pH loop of VP1 varied considerably in the extents of their FMDV antigenicity. Results from the sequencing of FMDV antigenic site 1 MAb neutralization-resistant mutants have shown that residues 144, 148, and 154 of VP1 contribute to the epitopes of MAbs B2, D7, 13DB, 13DD, and D9 (12, 15, 42) . Chimera 01.2 does not contain all of these residues; thus, the lack of MAb reactivity with this chimera is not surprising. The sequence inserted into chimera 01.1 does encompass these residues, but no reactivity with any of the FMDV site 1-specific MAbs was observed and only weak neutralizing reactivity was observed with polyclonal anti-FMDV serum. This suggests that other residues around this region contribute to the antibody epitopes or that the sequence adopts a conformation in the chimera which is not recognized by the antibodies. The results obtained with these chimeras are consistent with the findings from studies with synthetic peptides which suggested that the length of the peptide was important in determining the antivirus response (30) .
In contrast to the lack of reactivity of chimeras containing only part of antigenic site 1, chimera 01.3, which includes the entire VP1 residue 140 to 160 region of FMDV, was neutralized by a number of different FMDV-specific antibodies. This chimera was efficiently neutralized by polyclonal anti-FMDV serum and MAbs B2, 13DB, and D7, suggesting that the loop can adopt a conformation similar to that found in FMDV. In contrast, 01.3 reacted weakly with MAbs D9 and 13DD and polyclonal anti-residue 140 to 160 peptide serum. Between these two extremes, MAb B2 and polyclonal anti-FMDV serum efficiently neutralized this chimera but with a much lower titer than against FMDV. Some of these differences in reactivity can be explained by the fact that not all of the FMDV residues involved in antibody recognition are present in the pG-pH loop. This would obviously apply to the polyclonal anti-FMDV serum, but also MAb D9 is known to interact with residue 208 close to the C terminus of VP1 (42) . It was a surprise that anti-residue 140 to 160 peptide serum displayed only a weak neutralizing titer against chimera 01.3 but neutralized FMDV effectively. This serum can probably recognize a wide range of conformations of the peptide; it may be that this loop is more constrained in the chimera (and hence is recognized by fewer antibodies) than in FMDV, where the residue 138 to 157 region of VP1 has an undefined structure by crystallography (1) .
The selection of neutralization-resistant variants of chimera 01.3 by using MAb 13DB and polyclonal anti-FMDV serum, each containing a substitution of the residue corresponding to residue 148 of FMDV VP1, confirms the importance of this residue in the antigenicity of antigenic site 1. This residue has been previously shown to be important in studies using MAb neutralization-resistant variants of FMDV (37, 42) and in studies using synthetic peptides (29, 34) . This result further suggests that this sequence must be presented within the chimera in a manner highly analogous to that found in FMDV, despite the poor reactivity with the anti-residue 140 to 160 peptide serum discussed above.
01.3 induced significant FMDV-specific responses in all of the guinea pigs immunized with this chimera. The response was shown to be directed against FMDV antigenic site 1, since a much lower neutralization titer against site 1 mutants of FMDV was observed. In both immunization experiments, one of four guinea pigs was protected against FMDV challenge. Protection correlated with the highest levels of prechallenge anti-FMDV neutralizing antibody. This is the first demonstration of protection using a poliovirus antigen chimera containing an inserted sequence from another virus.
Chimeras 01.1 and 01.3 contain the RGD amino acid sequence, which is reported to be part of the cell attachment site of FMDV (9) . None of the chimeras had acquired the ability to grow on BHK, IBRS2 (pig kidney), or primary bovine thyroid cell monolayers. Furthermore, chimera 01.3 did not bind specifically to BHK cells, nor did preabsorption of this virus onto BHK cells block the ability of FMDV to infect the cells (data not shown).
Chimera 03.1 was recognized by neither anti-FMDV polyclonal serum nor antigenic site 3-specific MAbs. Antigenic site 3 of 01 K FMDV is a conformation-dependent site; MAbs which recognize this site react poorly, if at all, with subviral components or isolated proteins (15, 16, 18) . Amino acid substitutions which confer resistance to neutralization by site 3 MAbs have been identified only in the PiB-I3C loop of VP1 (12) . However, it is possibly that residues from loops adjacent to the fiB-I3C loop also contribute to the epitopes of site 3 MAbs, a situation that has been observed with the analogous antigenic site 1 of poliovirus (41) . Furthermore, residues from the adjacent VP1 PH-PI loop of type A1o and A12 FMDV have been shown to contribute to an analogous antigenic site (3, 39) . Therefore, the lack of reactivity of chimera 03.1 with FMDV-specific antibodies probably reflects the absence of residues which contribute to the epitopes of site 3 MAbs in the chimera. Despite this, chimera 03.1 was capable of inducing production of site 3-specific FMDV-neutralizing antibodies, implying that its structure The results obtained with this chimera further support our conclusion from the study of MAb neutralization-resistant mutants that VP1 residues 43 to 45 contribute to antigenic site 3 and that this site is distinct from antigenic site 1 (12 (27) . It seems likely that this is a nonspecific effect, since binding of this MAb in this assay was inhibited to the same degree by either trypsin-treated or untreated virus (2) . Trypsin treatment cleaves type 01 FMDV at residues 138, 154, and 200 of VP1 (38) , resulting in loss of residues 139 to 154 and 201 to 213 from the virus particle, consistent with the lack of reactivity of antipeptide serum in ELISA or radioimmune precipitation assays (27) . It should also be noted that previous studies from this laboratory (12, 42) and others (31, 37) The results obtained with chimera 03.1 suggest that it is possible to induce antibodies against conformation-dependent antigenic sites, as well as linear epitopes, by using poliovirus chimeras. The neutralizing response generated by these chimeras might be improved by introducing FMDV sequences at more than one site into the poliovirus structure. It is probable that such viruses can be generated, since it has been demonstrated that poliovirus antigenic site 2 can also be modified (24) . Bovine enterovirus is common in cattle and has now been cloned and sequenced (7) . The 
